Trial · NCT03065127
Registered outcomes21
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 21
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Gait Assessment | Change from Baseline at 4 weeks of first treatment phase | Participants will walk approximately 9.75 metres for 12 trials. Recording of kinematic data will be done with eight Optotrak® cameras (Northern Digital, NDI, Waterloo, Ontario). Spatiotemporal gait parameters will be analyzed from this assessment. |
| Primary | Gait Assessment | Change from Baseline at 4 weeks of second treatment phase | Participants will walk approximately 9.75 metres for 12 trials. Recording of kinematic data will be done with eight Optotrak® cameras (Northern Digital, NDI, Waterloo, Ontario). Spatiotemporal gait parameters will be analyzed from this assessment. |
| Primary | Gait Assessment | Change from Baseline at 4 weeks of third treatment phase | Participants will walk approximately 9.75 metres for 12 trials. Recording of kinematic data will be done with eight Optotrak® cameras (Northern Digital, NDI, Waterloo, Ontario). Spatiotemporal gait parameters will be analyzed from this assessment. |
| Secondary | Stroop Test | Pre-intervention and Post-intervention at week 4 of first treatment phase | This test assesses inhibitory control and will be administered in a paper-based format. |
| Secondary | Trail-making test | Pre-intervention and Post-intervention at week 4 of first treatment phase | This will also be administered in a paper-based format. This test will assess visuospatial function and set-shifting ability. |
| Secondary | Stroop Test | Pre-intervention and Post-intervention at week 4 of second treatment phase | This test assesses inhibitory control and will be administered in a paper-based format. |
| Secondary | Trail-making test | Pre-intervention and Post-intervention at week 4 of second treatment phase | This will also be administered in a paper-based format. This test will assess visuospatial function and set-shifting ability. |
| Secondary | Stroop Test | Pre-intervention and Post-intervention at week 4 of third treatment phase | This test assesses inhibitory control and will be administered in a paper-based format. |
| Secondary | Trail-making test | Pre-intervention and Post-intervention at week 4 of third treatment phase | This will also be administered in a paper-based format. This test will assess visuospatial function and set-shifting ability. |
| Secondary | Passive Joint Angle Matching | Pre-intervention and Post-intervention at week 4 of first treatment phase | This task will be assessed in order to evaluate proprioceptive functioning. |
| Secondary | Passive Joint Angle Matching | Pre-intervention and Post-intervention at week 4 of second treatment phase | This task will be assessed in order to evaluate proprioceptive functioning. |
| Secondary | Passive Joint Angle Matching | Pre-intervention and Post-intervention at week 4 of third treatment phase | This task will be assessed in order to evaluate proprioceptive functioning. |
| Secondary | Parkinson Anxiety Scale | Pre-intervention and Post-intervention at week 4 of first treatment phase | The Parkinson Anxiety Scale (PAS), which is a self-report questionnaire used to assess anxiety levels, will be administered to participants. This tool has demonstrated good concurrent validity in individuals with PD against other existing anxiety scales (Leentjens et al., 2014). |
| Secondary | Parkinson Anxiety Scale | Pre-intervention and Post-intervention at week 4 of second treatment phase | The Parkinson Anxiety Scale (PAS), which is a self-report questionnaire used to assess anxiety levels, will be administered to participants. This tool has demonstrated good concurrent validity in individuals with PD against other existing anxiety scales (Leentjens et al., 2014). |
| Secondary | Parkinson Anxiety Scale | Pre-intervention and Post-intervention at week 4 of third treatment phase | The Parkinson Anxiety Scale (PAS), which is a self-report questionnaire used to assess anxiety levels, will be administered to participants. This tool has demonstrated good concurrent validity in individuals with PD against other existing anxiety scales (Leentjens et al., 2014). |
| Secondary | Unified Parkinson's disease Rating Scale Motor Subsection (UPDRS-III) | Pre-intervention and Post-intervention at week 4 of first treatment phase | A clinician administered assessment which evaluates individuals' motor symptom severity |
| Secondary | Unified Parkinson's disease Rating Scale Motor Subsection (UPDRS-III) | Pre-intervention and Post-intervention at week 4 of second treatment phase | A clinician administered assessment which evaluates individuals' motor symptom severity |
| Secondary | Unified Parkinson's disease Rating Scale Motor Subsection (UPDRS-III) | Pre-intervention and Post-intervention at week 4 of third treatment phase | A clinician administered assessment which evaluates individuals' motor symptom severity |
| Secondary | New Freezing of Gait Questionnaire (NFOGQ) | Pre-intervention and Post-intervention at week 4 of first treatment phase | Participants will be asked to complete the New Freezing of Gait Questionnaire (NFOGQ) questionnaire developed by Nieuwboer and colleagues (2009). This provides a self-reported measure of frequency and duration of FOG episodes. This tool has been validated and proven to be highly reliable in individuals with PD, as well as assessing treatment interventions for FOG. |
| Secondary | New Freezing of Gait Questionnaire (NFOGQ) | Pre-intervention and Post-intervention at week 4 of second treatment phase | Participants will be asked to complete the New Freezing of Gait Questionnaire (NFOGQ) questionnaire developed by Nieuwboer and colleagues (2009). This provides a self-reported measure of frequency and duration of FOG episodes. This tool has been validated and proven to be highly reliable in individuals with PD, as well as assessing treatment interventions for FOG. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03065127/registered